Skip to main content
SpringerLink
Log in

Pharmacological Therapy: Novel Approaches

  • Chapter
  • First Online:
COPD

Part of the book series: Respiratory Medicine ((RM))

  • 5096 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2006) Global strategy for diagnosis, management and prevention of COPD. Am J Respir Crit Care Med 174:867–874

    Article  CAS  Google Scholar 

  2. Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23(6):932–946

    Article  CAS  PubMed  Google Scholar 

  3. Rennard SI (2004) Treatment of stable chronic obstructive pulmonary disease. Lancet 364(9436):791–802

    Article  CAS  PubMed  Google Scholar 

  4. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ (2003) Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 58(11):937–941

    Article  CAS  PubMed  Google Scholar 

  5. Anzueto A, Tashkin D, Menjoge S, Kesten S (2005) One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 18(2):75–81

    Article  CAS  PubMed  Google Scholar 

  6. Murray CJL, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge

    Google Scholar 

  7. Rubin BK, Fink JB (2005) Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 50(9):1191–1200

    PubMed  Google Scholar 

  8. Leach CL (2005) The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 50(9):1201–1208

    PubMed  Google Scholar 

  9. Smaldone GC (2005) Assessing new technologies: patient-device interactions and deposition. Respir Care 50(9):1151–1160

    PubMed  Google Scholar 

  10. Labiris NR, Dolovich MB (2003) Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56(6):600–612

    Article  CAS  PubMed  Google Scholar 

  11. Newman SP, Busse WW (2002) Evolution of dry powder inhaler design, formulation, and performance. Respir Med 96(5):293–304

    Article  CAS  PubMed  Google Scholar 

  12. Frijlink HW, De Boer AH (2004) Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 1(1):67–86

    Article  CAS  PubMed  Google Scholar 

  13. O’Donnell DE (2006) Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3(2):180–184

    Article  PubMed  Google Scholar 

  14. O’Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, Gelb AF, Mahler DA, Webb KA (2007) Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 4(2):145–168

    Article  PubMed  Google Scholar 

  15. Matera MG, Cazzola M (2007) Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 67(4):503–515

    Article  CAS  PubMed  Google Scholar 

  16. Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M (2007) Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 29(3):575–581

    Article  CAS  PubMed  Google Scholar 

  17. Agrawal DK, Ariyarathna K, Kelbe PW (2004) (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 113(3):503–510

    Article  CAS  PubMed  Google Scholar 

  18. Costello J (1999) Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol. J Allergy Clin Immunol 104(2 Pt 2):S61–S68

    CAS  PubMed  Google Scholar 

  19. Rennard SI (2000) Anticholinergic bronchodilators. In: Martin RJ, Kraft M (eds) Combination therapy for asthma and chronic obstructive pulmonary disease. Marcel Dekker, New York, pp 159–180

    Google Scholar 

  20. Hubner M, Hochhaus G, Derendorf H (2005) Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 25(3):469–488

    Article  PubMed  Google Scholar 

  21. Meltzer EO, Derendorf H (2006) The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. Ann Allergy Asthma Immunol 97(2):149–157

    Article  CAS  PubMed  Google Scholar 

  22. Humbert M (2004) Ciclesonide: a novel inhaled corticosteroid. Expert Opin Investig Drugs 13(10):1349–1360

    Article  CAS  PubMed  Google Scholar 

  23. Group, C. I. A. S. (1994) In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105:1411–1419

    Article  Google Scholar 

  24. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ (2005) Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26(2):214–222

    Article  PubMed  CAS  Google Scholar 

  25. Rennard SI (1999) Anticholinergics in combination bronchodilator therapy in COPD. In: Spector SL (ed) Anticholinergic agents in the upper and lower airways. Marcel Dekker, Inc., New York, pp 119–136

    Google Scholar 

  26. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T (2003) The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 124(3):834–843

    Article  CAS  PubMed  Google Scholar 

  27. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21(1):74–81

    Article  CAS  PubMed  Google Scholar 

  28. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356(8):775–789

    Article  CAS  PubMed  Google Scholar 

  29. Cushley MJ, Holgate ST (1985) Bronchodilator actions of xanthine derivatives administered by inhalation in asthma. Thorax 40(3):176–179

    Article  CAS  PubMed  Google Scholar 

  30. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O’Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA 272:1497–1505

    Article  CAS  PubMed  Google Scholar 

  31. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koeter GH, Timens W (2000) Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55(1):12–18

    Article  CAS  PubMed  Google Scholar 

  32. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W (2005) Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 26(5):835–845

    Article  CAS  PubMed  Google Scholar 

  33. Romberger DJ, Spurzem JR, Von Essen SG, Horstman D, Toso J, Hepp L, Stoner JA, Ullrich FA, Minton R, Matthews K, Rennard SI (2006) Impact of smoking cessation on quality of life measures in COPD. PATS 3:A811

    Google Scholar 

  34. Schnoll RA, Lerman C (2006) Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11(3):429–444

    Article  CAS  PubMed  Google Scholar 

  35. Lerman C, Patterson F, Berrettini W (2005) Treating tobacco dependence: state of the science and new directions. J Clin Oncol 23(2):311–323

    Article  PubMed  Google Scholar 

  36. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78(5):456–467

    Article  CAS  PubMed  Google Scholar 

  37. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1):47–55

    Article  CAS  PubMed  Google Scholar 

  38. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296(1):64–71

    Article  CAS  PubMed  Google Scholar 

  39. Fagerstrom K, Balfour DJ (2006) Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 15(2):107–116

    Article  PubMed  Google Scholar 

  40. Shapiro SD, Snider GL, Rennard SI (2005) Chronic Bronchitis and Emphysema. In: Mason RJ, Broadus VC, Murray JF, Nadel JA (eds) Textbook of respiratory medicine, 4th edn. Elsevier, Philadelphia, pp 1115–1167

    Google Scholar 

  41. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350(26):2645–2653

    Article  CAS  PubMed  Google Scholar 

  42. Anthonisen N, Connett J, Friedman B, Glass M, Kilday DP, Mingo TS, Rudolphus A, Williams GW (1991) Design of a clinical trial to test a treatment of the underlying cause of emphysema. Ann NY Acad Sci 624:31–34

    Article  PubMed  Google Scholar 

  43. Gross NJ (2004) Outcome measures for COPD treatments: a critical evaluation. COPD 1(1):41–57

    Article  PubMed  Google Scholar 

  44. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J (1999) A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160(5 Pt 1):1468–1472

    CAS  PubMed  Google Scholar 

  45. Barnes PJ (2004) Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56(4):515–548

    Article  CAS  PubMed  Google Scholar 

  46. White AJ, Gompertz S, Stockley RA (2003) Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 58(1):73–80

    Article  CAS  PubMed  Google Scholar 

  47. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH (1990) Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 85:682–689

    Article  CAS  PubMed  Google Scholar 

  48. Saetta M, Turato G, Facchini F, Corbino L, Maestrelli P, Mapp CE, Cavallesco G, Ciaccia A, Fabbri LM (1997) Macrophage and neutrophil infiltration in the bronchial glands of subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 155:A595

    Google Scholar 

  49. Barnes PJ (2007) New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 119(5):1055–1062, quiz 1063–1064

    Article  CAS  PubMed  Google Scholar 

  50. Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57(1):48–64

    CAS  PubMed  Google Scholar 

  51. Liu X, Rennard SI (2003) Therapeutic potential of PDE4 inhibitors in chronic obstructive pulmonary disease. Medscape

    Google Scholar 

  52. Rosenkranz S (2007) Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 96(8):527–541

    Article  CAS  PubMed  Google Scholar 

  53. Lewis GD, Semigran MJ (2004) Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep 1(4):183–189

    Article  PubMed  Google Scholar 

  54. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358(9278):265–270

    Article  CAS  PubMed  Google Scholar 

  55. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD (2005) Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366(9485):563–571

    Article  CAS  PubMed  Google Scholar 

  56. Rennard SI, Schachter N, Strek M, Rickard K, Amit O (2006) Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129(1):56–66

    Article  CAS  PubMed  Google Scholar 

  57. Giembycz MA (2002) 4D or not 4D – the emetogenic basis of PDE4 inhibitors uncovered? Trends Pharm Sci 23:548

    Article  CAS  PubMed  Google Scholar 

  58. Gutke HJ, Guse JH, Khobzaoui M, Renukappa-Gutke T, Burnet M (2005) AWD-12–281 (inhaled) (elbion/GlaxoSmithKline). Curr Opin Investig Drugs 6(11):1149–1158

    CAS  PubMed  Google Scholar 

  59. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson JD, Pavord ID, Rabe KF, Barnes NC, Jeffery PK (2003) Antiinflammatory effects of the phosphodiesterase 4 ihibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 168:976–982

    Article  PubMed  Google Scholar 

  60. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS, Rennard SI (2002) PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26(6):694–701

    CAS  PubMed  Google Scholar 

  61. MacNee W (2005) Oxidants and COPD. Curr Drug Targets Inflamm Allergy 4(6):627–641

    Article  CAS  PubMed  Google Scholar 

  62. Janoff A (1982) Reduction of the elastase in inhibitory capacity of alpha-1-antitrypsin by peroxides in cigarette smoke. An analysis of the brands and the filters. Am Rev Respir Dis 126:25–30

    Google Scholar 

  63. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470):1552–1560

    Article  CAS  PubMed  Google Scholar 

  64. Stoller JK, Aboussouan LS (2005) Alpha1-antitrypsin deficiency. Lancet 365(9478):2225–2236

    Article  CAS  PubMed  Google Scholar 

  65. Abusriwil H, Stockley RA (2006) Alpha-1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med 12(2):125–131

    Article  CAS  PubMed  Google Scholar 

  66. Lieberman J (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 118(5):1480–1485

    Article  CAS  PubMed  Google Scholar 

  67. Brantly M (2002) Alpha1-antitrypsin: not just an antiprotease: extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycol. Am J Respir Cell Mol Biol 27(6):652–654

    CAS  PubMed  Google Scholar 

  68. McElvaney NG, Crystal RG (1997) Proteases and lung injury. In: The lung: scientific foundations. Lippincott-Raven, Philadelphia

    Google Scholar 

  69. McElvaney NG, Crystal RG (1997) Antiproteases and lung defense. In: Crystal RG, West JB, Weibel ER, Barnes PJ (eds) The lung: scientific foundations. Lippincott-Raven, Philadelphia, pp 2219–2235

    Google Scholar 

  70. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R (2007) The safety and efficacy of Infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:926–934

    Article  CAS  PubMed  Google Scholar 

  71. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on infalmmatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542–548

    CAS  PubMed  Google Scholar 

  72. Di Francia M, Barbier D, Mege JL, Orehek J (1994) Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150:1453–1455

    PubMed  Google Scholar 

  73. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM (1996) Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153(2):633–637

    PubMed  Google Scholar 

  74. Keating GM, Perry CM (2002) Infliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 16(2):111–148

    Article  CAS  PubMed  Google Scholar 

  75. Tamaoki J, Kadota J, Takizawa H (2004) Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117(Suppl 9A):5S–11S

    CAS  PubMed  Google Scholar 

  76. Azuma A, Kudoh S (2006) Diffuse panbronchiolitis in East Asia. Respirology 11(3):249–261

    Article  PubMed  Google Scholar 

  77. Adcock IM, Ito K, Barnes PJ (2005) Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2(4):445–455

    Article  PubMed  Google Scholar 

  78. Barnes PJ (2006) Reduced histone deacetylase in COPD: clinical implications. Chest 129(1):151–155

    Article  CAS  PubMed  Google Scholar 

  79. Bonetti PO, Lerman LO, Napoli C, Lerman A (2003) Statin effects beyond lipid lowering – are they clinically relevant? Eur Heart J 24(3):225–248

    Article  CAS  PubMed  Google Scholar 

  80. Hothersall E, McSharry C, Thomson NC (2006) Potential therapeutic role for statins in respiratory disease. Thorax 61(8):729–734

    Article  CAS  PubMed  Google Scholar 

  81. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM (2006) Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47(12):2554–2560

    Article  CAS  PubMed  Google Scholar 

  82. SØyseth V, Brekke PH, Smith P, Omland T (2007) Statin use is associated with reduced mortality in COPD. Eur Respir J 29(2):279–283

    Article  PubMed  Google Scholar 

  83. Kollarik M, Undem BJ (2006) Sensory transduction in cough-associated nerves. Respir Physiol Neurobiol 152(3):243–254

    Article  PubMed  Google Scholar 

  84. Dougall IG, Young A, Ince F, Jackson DM (2003) Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale. Respir Med 97(Suppl A):S3–S7

    Article  PubMed  Google Scholar 

  85. Ind PW, Laitinen L, Laursen L, Wenzel S, Wouters E, Deamer L, Nystrom P (2003) Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms. Respir Med 97(Suppl A):S9–S21

    Article  PubMed  Google Scholar 

  86. Laursen LC, Lindqvist A, Hepburn T, Lloyd J, Perrett J, Sanders N, Rocchiccioli K (2003) The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation. Respir Med 97(Suppl A):S23–S33

    Article  PubMed  Google Scholar 

  87. Rogers DF, Barnes PJ (2006) Treatment of airway mucus hypersecretion. Ann Med 38(2):116–125

    Article  CAS  PubMed  Google Scholar 

  88. Adler KB, Li Y (2001) Airway epithelium and mucus: intracellular signaling pathways for gene expression and secretion. Am J Respir Cell Mol Biol 25(4):397–400

    CAS  PubMed  Google Scholar 

  89. Aliverti A, Ghidoli G, Dellaca RL, Pedotti A, Macklem PT (2003) Chest wall kinematic determinants of diaphragm length by optoelectronic plethysmography and ultrasonography. J Appl Physiol 94(2):621–630

    CAS  PubMed  Google Scholar 

  90. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF (1972) Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 286(17):912–918

    Article  CAS  PubMed  Google Scholar 

  91. Wouters EF (2002) Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 57(12):1067–1070

    Article  CAS  PubMed  Google Scholar 

  92. Lacasse Y, Goldstein R, Lasserson TJ, Martin S (2006) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD003793

    Google Scholar 

  93. Schols AM, Slangen J, Vovovics L, Wouters EF (1998) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1791–1797

    CAS  PubMed  Google Scholar 

  94. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier M, Storer TW (2004) Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170(8):870–878

    Article  PubMed  Google Scholar 

  95. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127(3):809–817

    Article  CAS  PubMed  Google Scholar 

  96. Massaro G, Massaro D (1997) Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 3:675–677

    Article  CAS  PubMed  Google Scholar 

  97. Massaro D, Massaro GD (2006) Toward therapeutic pulmonary alveolar regeneration in humans. Proc Am Thorac Soc 3(8):709–712

    Article  CAS  PubMed  Google Scholar 

  98. Meshi B, Vitalis TZ, Ionescu D, Elliott WM, Liu C, Wang XD, Hayashi S, Hogg JC (2002) Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 26(1):52–57

    CAS  PubMed  Google Scholar 

  99. Mao JT, Aberle D, Tashkin DP, Goldin J, Roth MD (2000) A phase II pilot study of all-trans retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 161:A583

    Google Scholar 

  100. Roth MD, Connett JE, D’Armiento JM, Foronjy RF, Friedman PJ, Goldin JG, Louis TA, Mao JT, Muindi JR, O’Connor GT, Ramsdell JW, Ries AL, Scharf SM, Schluger NW, Sciurba FC, Skeans MA, Walter RE, Wendt CH, Wise RA (2006) Feasibility of retinoids for the treatment of emphysema study. Chest 130(5):1334–1345

    Article  CAS  PubMed  Google Scholar 

  101. Shigemura N, Sawa Y, Mizuno S, Ono M, Ohta M, Nakamura T, Kaneda Y, Matsuda H (2005) Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats. Circulation 111(11):1407–1414

    Article  CAS  PubMed  Google Scholar 

  102. Ishizawa K, Kubo H, Yamada M, Kobayashi S, Numasaki M, Ueda S, Suzuki T, Sasaki H (2004) Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett 556(1–3):249–252

    Article  CAS  PubMed  Google Scholar 

  103. Rogers DF, Laurent GJ (1998) New ideas on the pathophysiology and treatment of lung disease. Thorax 53(3):200–203

    Article  CAS  PubMed  Google Scholar 

  104. Howell JE, McAnulty RJ (2006) TGF-beta: its role in asthma and therapeutic potential. Curr Drug Targets 7(5):547–565

    Article  CAS  PubMed  Google Scholar 

  105. Griffiths MJ, Bonnet D, Janes SM (2005) Stem cells of the alveolar epithelium. Lancet 366(9481):249–260

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Stephen I. Rennard

Authors
  1. Stephen I. Rennard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Section of Pulmonary and Critical Care M, Baylor College of Medicine, 1504 Taub Loop, Houston, 77030, Texas, USA

    Nicola A. Hanania

  2. Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd., Houston, 77030, Texas, USA

    Amir Sharafkhaneh

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rennard, S.I. (2011). Pharmacological Therapy: Novel Approaches. In: Hanania, N., Sharafkhaneh, A. (eds) COPD. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-59745-357-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-357-8_8

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-949-9

  • Online ISBN: 978-1-59745-357-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation